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Department of Surgery, Ohio State University, United StatesCongenital cardiac anomalies represent the most common birth de-
fect affecting nearly 1% of all live-births. Severe forms of congenital
heart disease are life-threatening and require surgical intervention. De-
spite signiﬁcant advances in the surgical and medical management of
this disease, it remains a leading cause of death in the newborn period
and lifelongmorbidity for survivors. One signiﬁcant source of morbidity
and mortality arises from complications associated with the use of cur-
rently available prosthetic vascular grafts, patches, and replacement
heart valves that are frequently needed to perform reconstructive pro-
cedures. These risks include a greater chance of thromboembolic com-
plications, poor durability due to neointimal hyperplasia, increased
susceptibility to infection, and lack of growth capacity. The develop-
ment of better biomaterials with growth potential could substantial-
ly improve the outcomes of children requiring congenital heart
surgery by reducing the number of graft-related complications and
enabling earlier deﬁnitive surgical repair without risk of serial re-
operation.
Tissue engineering offers an innovative solution to this signiﬁcant
problem. Using tissue engineering methods, bioprosthetics can be
made froman individual's own cells creating a livingmaterialwith excel-
lent biocompatibility and the ability to grow, repair, and remodel. One
promising approach utilized by several research groups is the use of a
biodegradable scaffold seeded with autologous cells. In 2001, our group
pioneered the development and translation of tissue-engineering tech-
nologies to create vascular grafts for use in the surgical repair of congen-
ital cardiac anomalies, using a biodegradable polymer conduit (Shinoka
et al., 2001; Hibino et al., 2010). de Mel and colleagues used a nanocom-
posite biomaterial-based small diameter vascular graft and induced
endothelialization in situ (de Mel et al., 2009). Thomas and Nair demon-
strated an electrospinning technique to generate biodegradable tubular
scaffolds for seeding vascular smooth muscle cells (Thomas and Nair,
2013). Our group is currently performing the ﬁrst FDA-approved clinical
trial evaluating the use of tissue engineered vascular grafts (TEVG) (IDE
14127). The TEVG ismade by seeding bonemarrow-derivedmononucle-
ar cells onto a biodegradable tubular scaffold.
In 2012, Olausson and colleagues described a novel and unique at-
tempt to develop tissue-engineered vein using decellularized allogenicDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.09.001.
⁎ Department of Cardiothoracic Surgery, The Heart Center, Nationwide Children's
Hospital, United States.
http://dx.doi.org/10.1016/j.ebiom.2014.10.001
2352-3964/ © 2014 The Author. Published by Elsevier B.V. This is an open access article undervein as the scaffold, and autologous endothelial and smooth muscle
cells differentiated from cultured mesenchymal stem cells obtained
from 20 mL of bone marrow, although the graft was narrowed at
1 year after the surgery and the patient required the second
application of new graft implantation (Olausson et al., 2012). Now
in EBioMedicine, they describe another clinical application of
bioengineered vascular graft using an autologous peripheral whole
blood instead of bone marrow cells, although one graft was also
explanted 7 months after initial surgery due to the narrowing. It is
indeed very challenging for any type of vascular conduit to maintain
the good patency in low-ﬂow venous system. In fact, our previous
clinical results also demonstrated that 4 out of 25 venous conduits
required balloon angioplasty due to narrowing in the long-term
periods (Hibino et al., 2010).
Many readers would be very interested in the histology of explanted
tissue in the patient andwould like to know the fate of seeded cells. We
have experience of using cultured endothelial cells for seeding our graft.
It was difﬁcult to maintain high quality-controlled production process
in a stable condition, especially for cell expansion of endothelial cells
in vitro. Despite the number of preparatory steps needed for the authors'
graft, the rewards look small. If the decellularized vein is easily available,
I would recommend trying to use bone marrow mononuclear cells ex-
pressing a cytokine effect to recruit host-derived endothelial cells and
smooth muscle cells onto the vein, so that the time-consuming cell ex-
pansion step can be eliminated. In fact, we demonstrated that the seeded
mononuclear cells in the vascular grafts were eventually replaced by cells
from adjacent vessels, probably via the body's innate healingmechanism,
resulting in neovessels of entirely host cell origin (Hibino et al., 2011).
Finally, I would like to congratulate the authors on this successful,
compassionate clinical application in these very difﬁcult patients for
whom conventional approaches were not feasible or hazardous.
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